Retatrutide Tracker App
Phase 3 Data Is In. Track What Matters.
Shotlee is the free way to track your protocol while retatrutide advances through Phase 3. In the first Phase 3 readout (TRIUMPH-4, December 11, 2025), the highest dose averaged 28.7% weight loss at 68 weeks with major improvements in knee osteoarthritis pain and function.
25,000+
GLP-1 Users Tracking
4.8★
App Rating
Free
Always Free to Use
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational triple receptor agonist developed by Eli Lilly that simultaneously activates GIP, GLP-1, and glucagon receptors. Unlike approved dual agonists such as tirzepatide (Mounjaro/Zepbound), the added glucagon component is designed to increase energy expenditure in addition to reducing appetite — potentially driving deeper weight loss in high-need populations.
Phase 2 data published in The New England Journal of Medicine (2023) reported up to 24.2% mean weight loss at 48 weeks. Phase 3 TRIUMPH-4 — the first readout from eight planned Phase 3 studies — exceeded that benchmark at 68 weeks and demonstrated simultaneous improvements in knee osteoarthritis pain and physical function, suggesting broad cardiometabolic utility.
Not Yet FDA Approved
As of March 2026, retatrutide remains investigational. TRIUMPH Phase 3 readouts are continuing through 2026. Use Shotlee to track your current protocol and baseline while awaiting availability.
Key Biohacking Mechanics
Triple receptor agonism for appetite suppression + metabolic energy expenditure
High responder potential in severe obesity cohorts (≥35% loss in 23.7%)
Meaningful pain and mobility improvements in knee OA patients
Phase 3 Snapshot: TRIUMPH-4 (68 Weeks)
Top weight loss result
28.7%
Mean reduction at 12 mg dose, equal to 71.2 lbs from a 248.5 lb average baseline.
Pain improvement
-75.8%
WOMAC pain score reduction at 9 mg in adults with obesity/overweight and knee OA.
Deep responder rate
39.4%
Participants on 12 mg who achieved at least 30% total body weight reduction.
TRIUMPH-4 Full Results
| Endpoint | Retatrutide 9 mg | Retatrutide 12 mg | Placebo |
|---|---|---|---|
| Mean weight change (68 weeks) | -26.4% | -28.7% | -2.1% |
| Mean pounds lost | -64.2 lbs | -71.2 lbs | -4.6 lbs |
| WOMAC pain score change | -4.5 points | -4.4 points | -2.4 points |
| Achieved ≥25% weight loss | 47.7% | 58.6% | 1.3% |
| Achieved ≥30% weight loss | 30.5% | 39.4% | 0.8% |
| Achieved ≥35% weight loss | 18.2% | 23.7% | 0.0% |
| Nausea rates | 38.1% | 43.2% | 10.7% |
| Discontinued due to adverse events | 12.2% | 18.2% | 4.0% |
Source: Eli Lilly Phase 3 TRIUMPH-4 topline announcement, December 11, 2025 [1]. Additional TRIUMPH readouts are expected throughout 2026.
TRIUMPH Development Timeline
2023
Global TRIUMPH Phase 3 program launched across obesity-related indications.
Dec 11, 2025
First positive Phase 3 readout (TRIUMPH-4) reported — obesity + knee OA co-primary endpoints met.
2026
Lilly expects seven additional Phase 3 readouts across obesity and type 2 diabetes.
Next
If later trials confirm efficacy and safety, regulatory submission and review can follow.
What to Track in Shotlee Right Now
Build clean baseline data today so you have a precise comparison point when retatrutide reaches approval.
Dose Logs
Record every injection date, dose, and site. Consistent logs reveal adherence patterns and timing effects.
Weekly Weight
Track weekly body weight to build your baseline trend. Compare your current drug vs future retatrutide results.
Side Effects
Log GI symptoms (nausea, vomiting, constipation) and their severity to share with your prescriber.
Body Measurements
Waist, hip, and neck circumference over time reveal fat redistribution even when scale weight plateaus.
Lab Snapshots
Record HbA1c, fasting glucose, lipids, and blood pressure from your clinic visits in one place.
Hunger & Energy
Daily appetite and energy ratings reveal how well your current protocol is controlling cravings.
What This Means for Your Tracking Right Now
Retatrutide now has early Phase 3 validation in a high-need obesity population, but it remains investigational. You cannot prescribe it yet outside trials. That makes your current protocol quality even more important.
Use Shotlee to build clean baseline data now: body weight trend, dose consistency, appetite changes, GI symptoms, blood pressure, body composition, and lab markers. If you later switch medications, that historical data lets you compare outcomes with precision instead of guesswork.
Shotlee supports current GLP-1 and dual agonist protocols today, so you can stay systematic while the remaining TRIUMPH Phase 3 results arrive through 2026.
Tracking Priorities in Shotlee
Weekly dose logs, side effect timing, body weight, waist measurements, and key lab snapshots are the highest-value signals to capture now in the Shotlee app.
Retatrutide vs Tirzepatide: Key Differences
Retatrutide (Triple Agonist)
- ⚡Targets GIP + GLP-1 + glucagon receptors
- ⚡28.7% mean weight loss at 68 weeks (Phase 3)
- ⚡Investigational — not yet FDA approved
- ⚡Unique glucagon component boosts energy expenditure
- ⚡Phase 3 TRIUMPH-4: co-primary OA endpoints met
Tirzepatide (Dual Agonist)
- ✓Targets GIP + GLP-1 receptors only
- ✓22.5% mean weight loss at 72 weeks (SURMOUNT-1)
- ✓FDA approved for obesity (Zepbound) and T2D (Mounjaro)
- ✓Proven real-world safety and efficacy data
- ✓Available now — track your protocol in Shotlee
Protocol FAQs
Lilly reported the first Phase 3 topline data from TRIUMPH-4 on December 11, 2025. At 68 weeks, participants on retatrutide 12 mg averaged 28.7% weight loss (71.2 lbs), while placebo averaged 2.1%. Shotlee helps you track your current treatment and prepare for this launch.
As of March 2026, retatrutide is still investigational and not FDA approved. TRIUMPH Phase 3 readouts are still ongoing. Use the Shotlee app to track this timeline and your current protocol.
Mounjaro and Zepbound use dual agonism (GIP + GLP-1). Retatrutide uses triple agonism (GIP + GLP-1 + glucagon), which adds increased energy expenditure on top of appetite control. Phase 3 data suggests deeper weight loss in high-need cohorts. Track and compare outcomes in Shotlee.
Track your current medication doses, side effects, body weight, measurements, and labs in Shotlee now, so you have solid baseline trend data if retatrutide becomes available. The Shotlee app keeps this history clean and easy to review with your prescriber.
Eli Lilly expects seven additional TRIUMPH Phase 3 readouts in 2026. Regulatory submission would follow if results confirm efficacy and safety. A realistic launch timeline — assuming a successful FDA filing — would be 2027 at the earliest. Follow Shotlee's tracker pages for updates.
References
Start Tracking Your Protocol Today
Build clean baseline data in Shotlee now. When retatrutide launches, you will have the history needed to compare outcomes with precision.
🚀 Use Shotlee for Free